ALTERATION OF BONE MINERAL DENSITY IN BREAST CANCER SURVIVORS TREATED WITH CHEMOTHERAPY: AN INTEGRATIVE REVIEW

VAZ-GONÇALVES, L. (Universidade Federal de Goiás), FARIA, S.S. (Universidade de Brasília), GODINHO-MOTA, J.C.M. (Universidade Federal de Goiás), MARTINS, K.A. (Universidade Federal de Goiás), FREITAS-JUNIOR, R. (Universidade Federal de Goiás)

Universidade Federal de GoiásChemotherapy for treatment of patients with breast cancer has increased the survival of this population. However they can significantly reduce bone mineral mass. The objective was to verify bone mineral density (BMD) modifications in women with breast cancer undergoing chemotherapy, as well as their clinical characteristics and risk factors. An integrative review of papers published from 2006 to 2016, carried out through specific terms in PubMed and SciELO databases. In that period, 898 papers were identified (897 in PubMed base and one in SciELO base). Among the six papers recovered, it was observed a considerable reduction in lumbar spine and femoral bone mass. The for women submitted to chemotherapy main regimes associated with the reduction were doxorubicin and cyclophosphamide (AC), cyclophosphamide, methotrexate and 5-fluorouracil, (CMF) and cyclophosphamide, epirubicin and 5-fluorouracil (FEC). In addition, there was a greater BMD reduction among women over 50 years, caucasian and who presented early ovarian failure induced by chemotherapy. It was concluded that use of chemotherapy for breast cancer may lead to bone mass loss, mainly when AC, CMF and FEC are used in women over 50 years and among those with early menopause united to this treatment.Bone mineral density, breast cancer, chemotherapy

Return